BioCentury
ARTICLE | Finance

Regulatory Milestones

Highlights of Weekly Biotech Stock Moves

December 20, 2010 8:00 AM UTC

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.72 (14%) to $22.79 last week after the European Medicines Agency's CHMP recommended approval of Xiapex collagenase clostridium histolyticum from Pfizer Inc. (NYSE:PFE) to treat Dupuytren's contracture in adult patients with a palpable cord. Pfizer has European marketing rights from Auxilium, which has worldwide rights from BioSpecifics Technologies Corp. (NASDAQ:BSTC). BioSpecifics shares were up $1.18 to $25.56 on the week.

Pharmaxis Ltd. (ASX:PXS) was off A$0.12 to A$2.79 last week after the Australian Advisory Committee on Prescription Medicines recommended approval of Bronchitol mannitol to treat cystic fibrosis (CF). Pharmaxis expects the Australian Therapeutic Goods Administration to make a decision early next year...